Sweet’s syndrome associated with FLT3 inhibition

Bibliografske podrobnosti
Main Authors:	Riyad N.H. Seervai, MD, PhD, Elena Paz Munoz, BS, S. Caleb Freeman, MD, Ronan I. Swords, MD, PhD, Kevin P. White, MD, Jesse J. Keller, MD, MCR
Format:	Article
Jezik:	English
Izdano:	Elsevier 2024-12-01
Serija:	JAAD Case Reports
Teme:	cutaneous toxicity FLT3 kinase inhibitor gilteritinib neutrophilic dermatosis oncodermatology quizartinib
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2352512624003801

Internet